Montelukast in hospitalized patients diagnosed with COVID-19
Authors:
- 4 March 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 59 (4) , 780-786
Abstract
Objective: Several therapeutic agents have been assessed for the treatment of COVID-19, but few approaches have been proven efficacious. Because leukotriene receptor antagonists such as montelukast have been shown to reduce both cytokine release and lung inflammation in preclinical models of viral influenza and acute respiratory distress syndrome, we hypothesized that therapy with montelukast could be used to treat COVID-19. The objective of this study was to determine if montelukast treatment would reduce the rate of clinical deterioration as measured by the COVID-19 Ordinal Scale. Methods: We performed a retrospective analysis of COVID-19 confirmed hospitalized patients treated with or without montelukast. We used “clinical deterioration” as the primary endpoint, a binary outcome defined as any increase in the Ordinal Scale value from Day 1 to Day 3 of hospital stay, as these data were uniformly available for all admitted patients before hospital discharge. Rates of clinical deterioration between the montelukast and non-montelukast groups were compared using the Fisher’s exact test. Univariate logistic regression was also used to assess the association between montelukast use and clinical deterioration. A total of 92 patients were analyzed, 30 received montelukast at the discretion of the treating physician and 62 patients who did not receive montelukast. Results: Patients receiving montelukast experienced significantly fewer events of clinical deterioration compared to patients not receiving montelukast (10% vs 32%, p = 0.022). Our findings suggest that montelukast associates with a reduction in clinical deterioration for COVID-19 confirmed patients as measured on the COVID-19 Ordinal Scale. Conclusions: Hospitalized COVID-19 patients treated with montelukast had fewer events of clinical deterioration, indicating that this treatment may have clinical activity. While this retrospective study highlights a potential pathway for COVID-19 treatment, this hypothesis requires further study by prospective studies.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Montelukast, Leukotriene Inhibitor, Reduces LPS-Induced Acute Lung Inflammation and Human Neutrophil ActivationArchivos de Bronconeumología, 2019
- Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial CellsPLOS Pathogens, 2017
- Antileukotrienes in Upper Airway Inflammatory DiseasesCurrent Allergy and Asthma Reports, 2015
- Study Of Montelukast For The Treatment Of Acute and Post Viral-Induced WheezingJournal of Allergy and Clinical Immunology, 2014
- A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthmaJournal of Allergy and Clinical Immunology, 2010
- Effect of montelukast on nuclear factor κB activation and proinflammatory moleculesAnnals of Allergy, Asthma & Immunology, 2005
- The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthmaEuropean Respiratory Journal, 2005
- Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroidsThorax, 1997